Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification

Background: In non-small cell lung cancer (NSCLC) patients harboring MET mutations, MET-tyrosine kinase inhibitors (TKIs) have been proven to achieve a good response. However, the relative efficacy of different therapeutics in primary NSCLC patients with MET amplification and the treatment options f...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Dantong, Tao, Junyan, Yan, Weihua, Zhu, Jingjuan, Zhou, Hai, Sheng, Yingying, Xue, Chaofan, Li, Hong, Hou, Helei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511535/
https://www.ncbi.nlm.nih.gov/pubmed/36148917
http://dx.doi.org/10.1177/15330338221128414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511535/
https://www.ncbi.nlm.nih.gov/pubmed/36148917
http://dx.doi.org/10.1177/15330338221128414

Ejemplares similares